In Milestone Trial, Experimental Drug Delays Type 1 Diabetes
A research effort spanning 33 years is reaching an important milestone when it comes to understanding type 1 diabetes treatment options.
The findings mark the first time the disease has been noticeably delayed in young people who are already at a high risk for developing the disease through an experimental drug. Researchers found that 2 weeks of an experimental intravenous (IV) drug can delay diabetes from developing by an average of about two years. This is a departure from the usual diabetes treatment: Insulin. While the findings are promising, there is still much more work to be done on this front. To learn more about this research, head on over to Science Magazine.